Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma

被引:1
|
作者
Nishimura, Noriko [1 ]
Brown, Samantha [2 ]
Devlin, Sean M. [3 ]
Dahi, Parastoo B. [4 ,5 ]
Landau, Heather [4 ,6 ]
Lahoud, Oscar B. [6 ]
Scordo, Michael [4 ,6 ]
Shah, Gunjan L. [4 ,7 ]
Hassoun, Hani [8 ]
Hultcrantz, Malin [8 ]
Korde, Neha [8 ]
Lesokhin, Alexander M. [5 ,9 ]
Mailankody, Sham [5 ]
Shah, Urvi A. [8 ]
Tan, Carlyn [8 ]
Usmani, Saad [10 ]
Giralt, Sergio A. [4 ,11 ]
Chung, David J. [4 ,6 ]
Gupta, Gaurav [12 ]
Maryamchik, Elena [12 ]
Ntrivalas, Evangelos [13 ]
Roshal, Mikhail [14 ]
机构
[1] Sloan Kettering Inst Canc Res, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol Biostat, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[4] Weill Cornell Med Coll, Dept Med, New York, NY USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, Cellular Therapy Serv, 1275 York Ave, New York, NY 10021 USA
[8] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
[9] Weill Cornell Med Coll, New York, NY USA
[10] Levine Canc Inst, New York, NY USA
[11] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, 1275 York Ave, New York, NY 10021 USA
[12] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Transfus Med & Cell Therapy, 1275 York Ave, New York, NY 10021 USA
[13] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Cellular Immunol Serv, 1275 York Ave, New York, NY 10021 USA
[14] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Hematopathol Serv, 1275 York Ave, New York, NY 10021 USA
关键词
D O I
10.1182/blood-2022-160271
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma
    Bal, Susan
    Landau, Heather J.
    Shah, Gunjan L.
    Scordo, Michael
    Dahi, Parastoo
    Lahoud, Oscar B.
    Hassoun, Hani
    Hultcrantz, Malin
    Korde, Neha
    Lendvai, Nikoletta
    Lesokhin, Alexander M.
    Mailankody, Sham
    Shah, Urvi A.
    Smith, Eric
    Devlin, Sean M.
    Avecilla, Scott
    Dogan, Ahmet
    Roshal, Mikhail
    Landgren, Ola
    Giralt, Sergio A.
    Chung, David J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (08) : 1394 - 1401
  • [2] Detection of Minimal Residual Disease in Autograft Is Prognostic of Survival Following Stem Cell Transplant in Multiple Myeloma
    Chu, Michael P.
    Baigorri, Eva
    Kriangkum, Jitra
    Hewitt, Joanne D.
    Belch, Andrew
    Venner, Christopher P.
    Sandhu, Irwindeep
    Pilarski, Linda M.
    BLOOD, 2017, 130
  • [3] Minimal residual disease testing after stem cell transplantation for multiple myeloma
    A M Sherrod
    P Hari
    C A Mosse
    R C Walker
    R F Cornell
    Bone Marrow Transplantation, 2016, 51 : 2 - 12
  • [4] Minimal residual disease testing after stem cell transplantation for multiple myeloma
    Sherrod, A. M.
    Hari, P.
    Mosse, C. A.
    Walker, R. C.
    Cornell, R. F.
    BONE MARROW TRANSPLANTATION, 2016, 51 (01) : 2 - 12
  • [5] Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
    Patel, Dilan A.
    Gopalakrishnan, Ragisha
    Engelhardt, Brian G.
    McArthur, Evonne
    Sengsayadeth, Salyka
    Culos, Katie A.
    Byrne, Michael
    Goodman, Stacey
    Savani, Bipin N.
    Chinratanalab, Wichai
    Jagasia, Madan
    Mosse, Claudio A.
    Cornell, Robert F.
    Kassim, Adetola A.
    BONE MARROW TRANSPLANTATION, 2020, 55 (06) : 1137 - 1146
  • [6] Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma
    Dilan A. Patel
    Ragisha Gopalakrishnan
    Brian G. Engelhardt
    Evonne McArthur
    Salyka Sengsayadeth
    Katie A. Culos
    Michael Byrne
    Stacey Goodman
    Bipin N. Savani
    Wichai Chinratanalab
    Madan Jagasia
    Claudio A. Mosse
    Robert F. Cornell
    Adetola A. Kassim
    Bone Marrow Transplantation, 2020, 55 : 1137 - 1146
  • [7] Monitoring of minimal residual disease among multiple myeloma patients after autologous stem cell transplantation
    Akhundova, F.
    Mendeleeva, L.
    Galtseva, I.
    Pokrovskaya, O.
    Urnova, E.
    Parovichnikova, E.
    Savchenko, V.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S258 - S259
  • [8] Multiple myeloma: Maintenance therapy after autologous stem cell transplantation, depending on minimal residual disease
    Solovyev, M. V.
    Mendeleeva, L. P.
    Pokrovskaya, O. S.
    Nareyko, M. V.
    Firsova, M. V.
    Galtseva, I. V.
    Davydova, Yu. O.
    Kapranov, N. M.
    Kuzmina, L. A.
    Gemdzhian, E. G.
    Savchenko, V. G.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 25 - 31
  • [9] Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
    Pianko, Matthew J.
    Devlin, Sean M.
    Littmann, Eric R.
    Chansakul, Aisara
    Mastey, Donna
    Salcedo, Meghan
    Fontana, Emily
    Line, Lilan
    Tavitian, Elizabet
    Slingerland, John B.
    Slingerland, Ann E.
    Clurman, Annelie
    Gomes, Antonio L. C.
    Taur, Ying
    Pamer, Eric G.
    Peled, Jonathan U.
    van den Brink, Marcel R. M.
    Landgren, Ola
    Lesokhin, Alexander M.
    BLOOD ADVANCES, 2019, 3 (13) : 2040 - 2044
  • [10] Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myeloma
    Campbell, Lauren
    Panitsas, Fotios
    Basu, Supratik
    Anyanwu, Francis
    Lee, Sophie
    Ferry, Berne
    Ramasamy, Karthik
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (04) : 775 - 778